Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

[1]  Y. Ishikawa,et al.  CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan , 2018, Oncotarget.

[2]  Y. Ishikawa,et al.  Relationship of tumor PD‐L1 (CD274) expression with lower mortality in lung high‐grade neuroendocrine tumor , 2017, Cancer medicine.

[3]  D. Sargent,et al.  Lack of Caudal‐Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer , 2017, Clinical colorectal cancer.

[4]  Debashis Sahoo,et al.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. , 2016, The New England journal of medicine.

[5]  N. Cho,et al.  Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. , 2015, World journal of gastroenterology.

[6]  I. Zlobec,et al.  Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high‐level CpG Island methylator phenotype and mismatch repair‐deficiency , 2014, International journal of cancer.

[7]  N. Cho,et al.  Loss of CDX2/CK20 Expression Is Associated With Poorly Differentiated Carcinoma, the CpG Island Methylator Phenotype, and Adverse Prognosis in Microsatellite-unstable Colorectal Cancer , 2013, The American journal of surgical pathology.

[8]  S. Kato,et al.  Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer , 2013, International Journal of Clinical Oncology.

[9]  Stephanie Grainger,et al.  Cdx function is required for maintenance of intestinal identity in the adult. , 2012, Developmental biology.

[10]  N. Kemeny,et al.  Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. , 2011, Critical reviews in oncology/hematology.

[11]  D. Kerr,et al.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Terracciano,et al.  Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis , 2010, International journal of cancer.

[13]  N. Kemeny,et al.  Role of adjuvant therapy after resection of colorectal cancer liver metastases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[15]  J. Barrett,et al.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Shuji Ogino,et al.  Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer , 2009, Clinical Cancer Research.

[17]  Stephanie Grainger,et al.  Cdx2 regulates patterning of the intestinal epithelium. , 2009, Developmental biology.

[18]  K. Kaestner,et al.  Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. , 2009, Developmental cell.

[19]  H. Frierson,et al.  Comprehensive Evaluation of CDX2 in Invasive Cervical Adenocarcinomas: Immunopositivity in the Absence of Overt Colorectal Morphology , 2008, The American journal of surgical pathology.

[20]  R. Labianca,et al.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Terracciano,et al.  Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status , 2008, Modern Pathology.

[22]  J. Bosset,et al.  Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Berlin,et al.  Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement , 2006, Annals of Surgical Oncology.

[24]  A. Flahault,et al.  Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression , 2003, Virchows Archiv.

[25]  Mårten Fernö,et al.  Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. , 2002, Archives of pathology & laboratory medicine.

[26]  Kathleen R. Cho,et al.  Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. , 2001, The American journal of pathology.

[27]  P. Traber,et al.  Cdx1 and cdx2 expression during intestinal development. , 2000, Gastroenterology.

[28]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[29]  F. Bosman,et al.  Comprar WHO Classification of Tumours of the Digestive System | F. Bosman | 9789283224327 | WHO World Health Organization , 2010 .

[30]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.